Communication autocrine : Questions médicales fréquentes
Nom anglais: Autocrine Communication
Descriptor UI:D019898
Tree Number:G04.085.100
Termes MeSH sélectionnés :
Cholangiocarcinoma
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Communication autocrine : Questions médicales les plus fréquentes",
"headline": "Communication autocrine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Communication autocrine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-27",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Communication autocrine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Communication cellulaire",
"url": "https://questionsmedicales.fr/mesh/D002450",
"about": {
"@type": "MedicalCondition",
"name": "Communication cellulaire",
"code": {
"@type": "MedicalCode",
"code": "D002450",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G04.085"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Communication autocrine",
"alternateName": "Autocrine Communication",
"code": {
"@type": "MedicalCode",
"code": "D019898",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mei Chen",
"url": "https://questionsmedicales.fr/author/Mei%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Dermatology and the USC-Norris Comprehensive Cancer Center, University of Southern California Keck Medical Centre, Los Angeles, CA, 90033, USA."
}
},
{
"@type": "Person",
"name": "Hamideh P Fallah",
"url": "https://questionsmedicales.fr/author/Hamideh%20P%20Fallah",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta, T2N 1N4, Canada."
}
},
{
"@type": "Person",
"name": "Hamid R Habibi",
"url": "https://questionsmedicales.fr/author/Hamid%20R%20Habibi",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, University of Calgary, 2500 University Drive NW, Calgary, Alberta, T2N 1N4, Canada. Electronic address: Habibi@ucalgary.ca."
}
},
{
"@type": "Person",
"name": "Michael Downes",
"url": "https://questionsmedicales.fr/author/Michael%20Downes",
"affiliation": {
"@type": "Organization",
"name": "Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037."
}
},
{
"@type": "Person",
"name": "Ronald M Evans",
"url": "https://questionsmedicales.fr/author/Ronald%20M%20Evans",
"affiliation": {
"@type": "Organization",
"name": "Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, CA 92037."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Haemobilia as a primary presentation of cholangiocarcinoma.",
"datePublished": "2024-08-29",
"url": "https://questionsmedicales.fr/article/39209753",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2024-260524"
}
},
{
"@type": "ScholarlyArticle",
"name": "New epidemiologic trends in cholangiocarcinoma.",
"datePublished": "2023-10-04",
"url": "https://questionsmedicales.fr/article/37797807",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clinre.2023.102223"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immune checkpoint inhibitors in cholangiocarcinoma.",
"datePublished": "2023-04-25",
"url": "https://questionsmedicales.fr/article/37096964",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2217/imt-2022-0288"
}
},
{
"@type": "ScholarlyArticle",
"name": "Heterogeneity of Cholangiocarcinoma Immune Biology.",
"datePublished": "2023-03-08",
"url": "https://questionsmedicales.fr/article/36980187",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cells12060846"
}
},
{
"@type": "ScholarlyArticle",
"name": "Liver Transplantation for Hilar Cholangiocarcinoma.",
"datePublished": "2023-10-20",
"url": "https://questionsmedicales.fr/article/37953035",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.suc.2023.09.004"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques cellulaires",
"item": "https://questionsmedicales.fr/mesh/D002468"
},
{
"@type": "ListItem",
"position": 3,
"name": "Communication cellulaire",
"item": "https://questionsmedicales.fr/mesh/D002450"
},
{
"@type": "ListItem",
"position": 4,
"name": "Communication autocrine",
"item": "https://questionsmedicales.fr/mesh/D019898"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Communication autocrine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Communication autocrine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Communication autocrine",
"description": "Comment diagnostiquer une communication autocrine ?\nQuels tests sont utilisés pour évaluer la communication autocrine ?\nY a-t-il des marqueurs spécifiques pour la communication autocrine ?\nLa communication autocrine est-elle visible par imagerie ?\nQuels sont les signes d'une dérégulation autocrine ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Communication autocrine",
"description": "Quels symptômes indiquent une communication autocrine anormale ?\nLa communication autocrine affecte-t-elle le métabolisme ?\nY a-t-il des symptômes spécifiques liés à l'autocrine dans le cancer ?\nComment la communication autocrine influence-t-elle l'immunité ?\nDes symptômes neurologiques peuvent-ils être liés à l'autocrine ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Communication autocrine",
"description": "Comment prévenir les dérégulations autocrines ?\nY a-t-il des mesures préventives spécifiques pour le cancer ?\nL'exercice physique aide-t-il à réguler l'autocrine ?\nLe stress influence-t-il la communication autocrine ?\nDes compléments alimentaires peuvent-ils aider ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Communication autocrine",
"description": "Quels traitements ciblent la communication autocrine ?\nLes médicaments peuvent-ils moduler la communication autocrine ?\nY a-t-il des traitements spécifiques pour le cancer liés à l'autocrine ?\nComment la thérapie génique influence-t-elle l'autocrine ?\nLes traitements hormonaux affectent-ils la communication autocrine ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Communication autocrine",
"description": "Quelles complications peuvent résulter d'une communication autocrine anormale ?\nLa communication autocrine peut-elle entraîner des troubles métaboliques ?\nY a-t-il des risques d'inflammation chronique ?\nComment la communication autocrine affecte-t-elle le cancer ?\nDes complications neurologiques sont-elles possibles ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Communication autocrine",
"description": "Quels sont les facteurs de risque de dérégulation autocrine ?\nL'alimentation influence-t-elle la communication autocrine ?\nLe stress est-il un facteur de risque ?\nY a-t-il des prédispositions génétiques ?\nL'exposition à des produits chimiques est-elle un risque ?",
"url": "https://questionsmedicales.fr/mesh/D019898?mesh_terms=Cholangiocarcinoma&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une communication autocrine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests biologiques et des analyses de signalisation cellulaire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la communication autocrine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de culture cellulaire et des dosages de cytokines peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour la communication autocrine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des marqueurs comme les récepteurs de cytokines peuvent indiquer une communication autocrine."
}
},
{
"@type": "Question",
"name": "La communication autocrine est-elle visible par imagerie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle n'est généralement pas visible par imagerie, mais des techniques avancées peuvent aider."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une dérégulation autocrine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes incluent une croissance cellulaire anormale ou une inflammation persistante."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une communication autocrine anormale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure des douleurs, des inflammations ou des tumeurs."
}
},
{
"@type": "Question",
"name": "La communication autocrine affecte-t-elle le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut influencer le métabolisme cellulaire et provoquer des déséquilibres."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques liés à l'autocrine dans le cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la fatigue et la perte de poids peuvent être présents."
}
},
{
"@type": "Question",
"name": "Comment la communication autocrine influence-t-elle l'immunité ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut moduler la réponse immunitaire, entraînant une inflammation ou une immunosuppression."
}
},
{
"@type": "Question",
"name": "Des symptômes neurologiques peuvent-ils être liés à l'autocrine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison de la signalisation autocrine."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dérégulations autocrines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et un mode de vie sain peuvent aider à prévenir ces dérégulations."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques pour le cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les carcinogènes et maintenir un poids santé sont des mesures préventives."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à réguler l'autocrine ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut moduler la signalisation autocrine et améliorer la santé cellulaire."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il la communication autocrine ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la communication autocrine et affecter la santé."
}
},
{
"@type": "Question",
"name": "Des compléments alimentaires peuvent-ils aider ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains compléments, comme les oméga-3, peuvent moduler la communication autocrine."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent la communication autocrine ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des inhibiteurs de signalisation peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils moduler la communication autocrine ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent inhiber ou stimuler la signalisation autocrine."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour le cancer liés à l'autocrine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les anticorps monoclonaux ciblent souvent la communication autocrine dans le cancer."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique influence-t-elle l'autocrine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique peut corriger des dérégulations dans la communication autocrine."
}
},
{
"@type": "Question",
"name": "Les traitements hormonaux affectent-ils la communication autocrine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements hormonaux peuvent influencer la signalisation autocrine dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter d'une communication autocrine anormale ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des maladies auto-immunes et des inflammations chroniques."
}
},
{
"@type": "Question",
"name": "La communication autocrine peut-elle entraîner des troubles métaboliques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une dérégulation peut provoquer des troubles métaboliques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques d'inflammation chronique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une communication autocrine anormale peut entraîner une inflammation chronique."
}
},
{
"@type": "Question",
"name": "Comment la communication autocrine affecte-t-elle le cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut favoriser la croissance tumorale et la résistance aux traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dérégulations peuvent entraîner des troubles neurologiques et cognitifs."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de dérégulation autocrine ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, l'obésité, le tabagisme et l'exposition à des toxines."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle la communication autocrine ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en sucres et graisses peut perturber la signalisation autocrine."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter le risque de dérégulation autocrine."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations génétiques peuvent prédisposer à des dérégulations autocrines."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques est-elle un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des produits chimiques toxiques peut augmenter le risque de dérégulation."
}
}
]
}
]
}
We present a case of haemobilia as a primary presentation for underlying cholangiocarcinoma. A man in his 50s initially presented to emergency with Quincke's triad, RUQ pain, jaundice and UGI bleeding...
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy and the second most frequent primary hepatic malignancy after hepatocellular carcinoma. During the past three decades, the incidenc...
Cholangiocarcinoma is an epithelial malignancy originating in the biliary tracts and frequently recurs even with surgical resection. Unresectable disease has a 5-year overall survival of less than 10%...
Cholangiocarcinomas (CCAs) are aggressive tumors arising along the biliary tract epithelium, whose incidence and mortality are increasing. CCAs are highly desmoplastic cancers characterized by a dense...
Hilar cholangiocarcinoma (hCCA) is an infiltrative disease that often presents with locally advanced and/or metastatic disease, with a minority of patients eligible for surgical resection. Select pati...
Vascular resection (VR) is extended surgery to attain a negative radial margin (RM) for distal cholangiocarcinoma (DCC). The present study explored the significance of VR for DCC, focusing on VR, RM, ...
Patients with DCC who underwent resection between 2002 and 2019 were reviewed....
Among 230 patients, 25 received VR. The overall survival (OS) in the VR group was significantly worse than in the non-VR group (16.7% vs. 50.7% at 5 years, P < 0.001). Patients who underwent VR with a...
VR for DCC was associated with a poor prognosis, even if a negative RM was obtained. VR is not necessary for DCC when the vessels are detachable from the tumor....
Regardless of anatomic origin, cholangiocarcinoma is generally an aggressive malignancy with a relatively high case fatality. Surgical resection with curative intent remains the best opportunity to ac...
Cholangiocarcinoma is a rare malignancy of the biliary tract with a relatively poor prognosis. As a gastroenterologist, our main role is to differentiate between benign and malignant biliary disease, ...
Intrahepatic cholangiocarcinoma (iCCA) tends to be asymptomatic until late stages, leading most of the patients to present at advanced stages of the disease. A combination of medical and surgical ther...